Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Lars Fruergaard Jørgensen, Novo Nordisk’s chief executive, said the company had now secured insurance coverage for Wegovy for about 55mn Americans with obesity, and the drug had been launched ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

including obesity. The Phase 2b results for the drug, monlunabant, were tucked into Novo Nordisk’s report of full-year 2024 financial results released Wednesday. The company said the once-daily ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the ...